No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Pfizer Cuts Spending on Weaker Sales
Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com
Sector Update: Health Care
Pfizer CEO Says Tariff Uncertainty Is Deterring Further U.S. Investment in Manufacturing, R&D